Abstract:Background & Aims: Liver disease is a rising cause of mortality worldwide. Primary human hepatocytes (PHH) and hepatocellular cancer cells are currently used in drug development, however, they come with limitations, including limited supply, rapid loss of function, and tumorigenic origin. In addition, current iPSC differentiation protocols lead to the generation of hepatocyte-like cells with compromised liver-related features. We hypothesised that optimisation of iPSC differentiation protocols can lead to the generation of hepatocyte-like cells with improved metabolic functionality for disease modelling and toxicity screening studies. Methods: Healthy human iPSCs were differentiated to hepatocyte-like cells (Opti-HEP) using a novel 3-step differentiation protocol. Hepatocyte functionality was assessed, including liver maturity marker expression, urea synthesis, de novo gluconeogenesis, and CYP450 expression, activity, and induction. Suitability of Opti-HEP to predict drug-induced liver injury (DILI) was evaluated by cell viability assays. CRISPR/Cas9 gene editing was employed to generate in vitro inherited metabolic disease models. Results: Opti-HEP expressed similar liver maturity marker levels to those seen in primary human hepatocytes (PHH), in addition to functional urea and gluconeogenesis pathways. CYP450 expression and activity were comparable between Opti-HEP and PHH, with both cell types showing similar levels of CYP3A4 induction upon 1α,25-hydroxy-vitamin D3 treatment. Opti-HEP accurately predicted DILI, following treatment with 7 drugs of known DILI liability. CRISPR-derived Opti-HEP harbouring mutations for inherited metabolic disorders (Ornithine Transcarbamylase Deficiency, Progressive Familial Intrahepatic Cholestasis Type 2, Citrullinemia Type 1) recapitulated key pathophysiological disease features, including reduced protein expression, impaired urea secretion, and bile acid transport. Conclusions: We demonstrate the generation of optimised iPSC-derived hepatocytes with enhanced liver functionality that is comparable to PHH. These data alongside the expansion capacity and amenability of these cells highlight the opportunities this model can offer in the space of disease modelling and large-scale drug efficacy and hepatotoxicity screening.

Primary Hepatocytes: Current Understanding of the Regulation of Metabolic Enzymes and Transporter Proteins, and Pharmaceutical Practice for the Use of Hepatocytes in Metabolism, Enzyme Induction, Transporter, Clearance, and Hepatotoxicity Studies

Factors Influencing Stem Cell Differentiation into the Hepatic Lineage in Vitro

Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device

Human Hepatocytes Isolated from Explanted Livers: A Powerful Tool to Understand End-stage Liver Disease and Drug Screening

In Vitro Culture of Isolated Primary Hepatocytes and Stem Cell-Derived Hepatocyte-Like Cells for Liver Regeneration

Expansion, in vivo-ex vivo cycling, and genetic manipulation of primary human hepatocytes

Three-dimensional Culture of Hepatocytes for Prediction of Drug-Induced Hepatotoxicity

Human hepatocyte transplantation for liver disease: current status and future perspectives

Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease

In VitroandIn VivoHepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases

Novel Therapeutic Modalities For Hepatic Diseases

Developing high-fidelity hepatotoxicity models from pluripotent stem cells

Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis

Two Effective Routes For Removing Lineage Restriction Roadblocks: From Somatic Cells To Hepatocytes

Development of optimised human iPSC-derived hepatocytes with improved liver function for in vitro metabolic disease modelling and toxicity studies

Current Status and Challenges of Human Induced Pluripotent Stem Cell-Derived Liver Models in Drug Discovery

Induction and Maturation of Hepatocyte-Like Cells in Vitro: Focus on Technological Advances and Challenges.

Current Strategies to Generate Mature Human Induced Pluripotent Stem Cells Derived Cholangiocytes and Future Applications

Similarities and Differences in the Expression of Drug-Metabolizing Enzymes Between Human Hepatic Cell Lines and Primary Human Hepatocytes.